Subject(s)
Cholangitis/etiology , Foreign Bodies/complications , Adult , Cholangitis/microbiology , Humans , Male , Moraxella , Neisseriaceae InfectionsSubject(s)
Endoscopy/adverse effects , Gastrostomy/adverse effects , Stomach Diseases/etiology , Aged , Aged, 80 and over , Gastric Mucosa , Humans , Male , SyndromeABSTRACT
Forty-eight patients successfully completed a six-week, double blind, placebo controlled trial of ranitidine hydrochloride 200mg twice daily for active duodenal ulceration. Following endoscopy 68% of the patients taking ranitidine had healed, compared to 35% of those who were taking placebo. Nineteen of the patients who had not healed then took a further six weeks of open active treatment; of these, 14 were successfully treated. Thirty-one of the patients who had healed duodenal ulcers then took ranitidine hydrochloride 100mg at night as a maintenance treatment for one year: 71% remained endoscopically and symptomatically in remission. No serious side effects were encountered.
Subject(s)
Anti-Ulcer Agents/therapeutic use , Duodenal Ulcer/drug therapy , Furans/therapeutic use , Histamine H2 Antagonists/therapeutic use , Adult , Clinical Trials as Topic , Double-Blind Method , Female , Humans , Male , Middle Aged , RanitidineSubject(s)
Dilatation , Esophageal Stenosis/therapy , Self Care/instrumentation , Aged , Endoscopes , Female , Humans , Male , Middle AgedSubject(s)
Cimetidine/pharmacology , Furans/pharmacology , Gastric Acid/metabolism , Guanidines/pharmacology , Histamine H2 Antagonists/pharmacology , Insulin/pharmacology , Pentagastrin/pharmacology , Cimetidine/administration & dosage , Furans/administration & dosage , Histamine H2 Antagonists/administration & dosage , Humans , Injections, Intravenous , Insulin/administration & dosage , Pentagastrin/administration & dosage , Pepsin A/metabolism , RanitidineABSTRACT
Fifty-one patients with duodenal ulcer which was healed by a six-week course of cimetidine completed a one-year double-blind study to compare the effects of cimetidine and placebo on the prevention of ulcer relapse. Patients were allocated at random to receive either 400 mg of cimetidine twice daily or placebo. Ulcer relapse was assessed by regular clinical follow up and endoscopy. A total of six of the 24 cimetidine-treated patients (25%) suffered a relapse compared to 25 of the 27 of placebo-treated patients (92.6%). Out of this total number of relapses, asymptomatic relapse with ulceration discovered by routine endoscopy at six months or one year, occurred in three patients receiving cimetidine and eight patients receiving placebo. Cimetidine prevents recurrence in patients with duodenal ulcer disease.
Subject(s)
Cimetidine/therapeutic use , Duodenal Ulcer/prevention & control , Guanidines/therapeutic use , Adult , Antacids/therapeutic use , Cimetidine/adverse effects , Clinical Trials as Topic , Double-Blind Method , Duodenal Ulcer/diagnosis , Endoscopy , Female , Humans , Male , Middle Aged , Placebos , RecurrenceABSTRACT
A case of a patient with Crohn's disease who was treated with azathioprine, and developed intestinal Hodgkin's disease as a complication is described.
